India’s Dr. Reddy’s To Focus On Providing Niche Services
This article was originally published in PharmAsia News
Executive Summary
Dr. Reddy's Laboratories of India plans to change the way it does business, focusing on niche services to gain an edge in the highly competitive generic drugs business. As a lead-up to the new emphasis, the company has combined its custom pharmaceutical services with its division for active pharmaceutical ingredients. The new division is called Pharmaceutical Services and Active Ingredients. A senior vice president at Dr. Reddy's, Abhijit Mukerjee, is to head the new division, and says the move is intended to take advantage of "a huge wealth of expertise." His division plans to provide research and manufacturing services matched to its clients, many of the services involving chemical molecules. (Click here for more
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.